In Reply We thank Tian et al for their letter and interest in our article.1 We agree with the authors that ex vivo lung perfusion (EVLP), regardless of platform, has consistently been shown to provide short-term outcomes similar to those of conventional lung transplantation.2,3 In our article, we focused on the longer-term outcomes, and these too were similar between EVLP-treated and non-EVLP donor lungs.
Identify all potential conflicts of interest that might be relevant to your comment.
Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.
Err on the side of full disclosure.
If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.
Not all submitted comments are published. Please see our commenting policy for details.
Tikkanen JM, Divithotawela C, Cypel M. Should All Donors Be Treated by Ex Vivo Lung Perfusion?—Reply. JAMA Surg. 2020;155(6):535–536. doi:10.1001/jamasurg.2020.0049
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: